Article
Oncology
Barry W. Goy, Sajjad Syed, Aswini Padmanabhan, Raoul J. Burchette, Chris S. Helmstedter
Summary: A comparison was made between Ifosfamide-Doxorubicin and local therapy for high-grade primary soft tissue sarcoma, with results suggesting that Ifosfamide-Doxorubicin may be more beneficial for younger patients with Synovial-Cell, DDL, Myxofibrosarcoma, RCLS, UPS, and US-NOS.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Bi-Cheng Wang, Bo-Hua Kuang, Bo-Ya Xiao, Guo-He Lin
Summary: In this study, the addition of ifosfamide to doxorubicin/adriamycin did not show significant benefits for patients with advanced soft tissue sarcoma in first-line treatment, even with comparable tolerability.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Yuki Kojima, Tatsunori Shimoi, Takuji Seo, Shu Yazaki, Toshihiro Okuya, Yohei Ohtake, Hitomi S. Okuma, Akihiko Shimomura, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Emi Noguchi, Kenji Tamura, Akihiko Yoshida, Shintaro Iwata, Eisuke Kobayashi, Akira Kawai, Yasuhiro Fujiwara, Kan Yonemori
Summary: This study aimed to evaluate the outcomes of second-line chemotherapy for patients with synovial sarcoma (SS). The overall response rate of second-line chemotherapy regimens for SS was 9.4%, and 34.3% of patients achieved disease control for more than 6 months. However, the study found that the current second-line chemotherapy regimens were not satisfactory, highlighting the urgent need for developing more effective therapeutic strategies for SS.
Article
Oncology
Ghazal Tansir, Sameer Rastogi, Akash Kumar, Adarsh Barwad, Asit R. Mridha, Ekta Dhamija, Shamim A. Shamim, Sushma Bhatnagar, Sandeep Bhoriwal
Summary: This study evaluates the efficacy, tolerability, and quality of life with the combination of gemcitabine and docetaxel in advanced, relapsed synovial sarcoma patients. The therapy produced clinically meaningful outcomes and met the primary endpoint of 3-month progression-free rate. These results should encourage further studies.
Review
Oncology
Joseph R. R. Fuchs, Brian C. C. Schulte, Jeffrey W. W. Fuchs, Mark Agulnik
Summary: Synovial sarcoma is a soft tissue sarcoma with approximately 1,000 cases per year in the United States. Current standard treatment involves anthracycline-based chemotherapy for advanced and metastatic synovial sarcoma. However, the survival rates remain poor, prompting the need for potential targets for treatment.
FRONTIERS IN ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Mengmeng Liu, Quan Li, Yao Liang
Summary: Several studies have identified pyroptosis as a potential target for cancer treatment. This study specifically focuses on the role of pyroptosis-related genes (PRGs) in soft tissue sarcoma (STS) and evaluates their interactions, biological functions, and prognostic values. Through analysis, a five-gene survival related-risk score is created and validated in different cohorts. A nomogram is also developed to predict prognosis and therapeutic responses, and the study suggests that immunotherapy is more beneficial for patients with minimal risk of PRGs. Additionally, effective chemotherapy and targeted drugs sensitive to high-risk populations are identified.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Nicholas D. Klemen, Sinchun Hwang, Martina Bradic, Evan Rosenbaum, Mark A. Dickson, Mrinal M. Gounder, Ciara M. Kelly, Mary L. Keohan, Sujana Movva, Katherine A. Thornton, Ping Chi, Benjamin A. Nacev, Jason E. Chan, Edmund K. Bartlett, Allison L. Richards, Samuel Singer, Mark T. A. Donoghue, William D. Tap, Sandra P. D'Angelo
Summary: This study analyzed the response to PD-1 blockade in advanced sarcoma patients, finding that it can result in durable responses but may also lead to hyperprogressive disease (HPD). The clinical and biological characteristics of HPD in sarcoma patients were similar to those with progressive disease (PD), highlighting the need for further research into HPD as a distinct phenomenon.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Do Weon Lee, Han-Soo Kim, Ilkyu Han
Summary: The study found that actual 5-year survival in stage III soft tissue sarcoma patients is associated with tumor size, histological grade, and ASA score. Nevertheless, the majority of long-term survivors still exhibit factors of poor prognosis.
Article
Medicine, General & Internal
Cecilia Tetta, Grazia Montrone, Alessandra Longhi, Michele Rocca, Francesco Londero, Gianmarco Parise, Orlando Parise, Jos G. Maessen, Marco Miceli, Sandro Gelsomino
Summary: For patients with HGSS, adjuvant chemotherapy did not show any advantage in terms of freedom from SS-specific mortality, and was associated with a higher risk of SS-specific mortality.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Oncology
Maria L. Inchaustegui, Kelly Kon-Liao, Kim Ruiz-Arellanos, George Aquilino E. Silva, Marcos R. Gonzalez, Juan Pretell-Mazzini
Summary: This systematic review analyzed the treatment options and outcomes for patients with radiation-induced soft tissue sarcomas (RISs). The most common treatment for RISs was surgery, with chemotherapy and radiotherapy used less frequently. Patients with RISs had a low 5-year survival rate, and high rates of local recurrence and cancer spreading.
Review
Oncology
Lorena Landuzzi, Maria Cristina Manara, Laura Pazzaglia, Pier-Luigi Lollini, Katia Scotlandi
Summary: Synovial sarcoma (SyS) is a rare aggressive soft tissue sarcoma with a unique genetic signature. The majority of patients are initially diagnosed with localized disease, but metastatic relapse is common and advanced stages have a poor prognosis. This review summarizes current treatments and highlights the potential of new epigenetic and immunological strategies. Accurate patient selection based on genetic and tumor immune microenvironment signatures is crucial.
Review
Pharmacology & Pharmacy
Tomoki Nakamura, Akihiro Sudo
Summary: Trabectedin is a safe and effective therapeutic option for patients with advanced STS. While it may be effective as first-line treatment in selected patients, doxorubicin remains the preferred choice for locally advanced or metastatic STS.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Bushu Xu, Qiuzhong Pan, Hua Pan, Haomiao Li, Xianan Li, Jing Chen, Danmei Pang, Baoqing Zhang, Desheng Weng, Ruiqing Peng, Meiyu Fang, Xing Zhang
Summary: This study evaluated the efficacy and safety of anlotinib as a maintenance treatment for advanced STS after chemotherapy. The results showed that anlotinib maintenance treatment had promising efficacy and tolerable toxicity in patients with advanced STS.
Article
Oncology
Monika Scheer, Erika Hallmen, Christian Vokuhl, Joerg Fuchs, Per-Ulf Tunn, Marc Muenter, Beate Timmermann, Sebastian Bauer, Anton George Henssen, Bernarda Kazanowska, Felix Niggli, Ruth Ladenstein, Gustaf Ljungman, Angelika Eggert, Thomas Klingebiel, Ewa Koscielniak
Summary: This study evaluated the effects of neoadjuvant or adjuvant radiation therapy and surgery only on long-term outcomes in patients with synovial sarcoma. The results showed that the best local control was achieved when tumors were irradiated pre-operatively and underwent R0 or R1 resection thereafter.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Rajkumar Venkatramani, Wei Xue, R. Lor Randall, Suzanne Wolden, James Anderson, Dolores Lopez-Terrada, Jennifer Black, Simon C. Kao, Barry Shulkin, Andrew Ostrenga, Alberto Pappo, Sheri L. Spunt
Summary: The risk-based treatment strategy used in this study showed favorable outcomes in patients with synovial sarcoma, especially in nonmetastatic cases, despite using radiation therapy less frequently and at lower doses compared to historical controls.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Computer Science, Interdisciplinary Applications
Anne Dirkson, Suzan Verberne, Gerard van Oortmerssen, Hans Gelderblom, Wessel Kraaij
Summary: Patients share coping strategies for illnesses in online support groups. Automatic extraction of these strategies from patient discussion groups has not been attempted before. This study introduces a new task that faces challenges such as complex entities, numerous labels, and relations between documents. The authors present an initial ontology for coping strategies and compare two computational solutions for this task. The evaluation results show limited performance, with multi-label classification outperforming named entity recognition with entity linking.
JOURNAL OF BIOMEDICAL INFORMATICS
(2023)
Correction
Oncology
Dario Callegaro, Alessandro Gronchi
ANNALS OF SURGICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Herbert H. Loong, Abha Gupta, Alessandro Gronchi
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Stefano Radaelli, Marco Baia, Ashley Drohan, Carlo Morosi, Claudia Sangalli, Chiara Colombo, Dario Callegaro, Marco Fiore, Alessandro Gronchi
Summary: This study presents a reproducible and standardized six-stage approach for the surgical treatment of primary retroperitoneal liposarcoma. The patient underwent en bloc resection of the retroperitoneal mass along with the kidney, adrenal gland, colon, psoas muscle, and diaphragm. Resection of retroperitoneal sarcoma is a complex procedure that requires a broad range of surgical expertise.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Luca Improta, Sandro Pasquali, Sara Iadecola, Marta Barisella, Marco Fiore, Stefano Radaelli, Chiara Colombo, Rossana Alloni, Dario Callegaro, Sergio Valeri, Rosalba Miceli, Alessandro Gronchi
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Robbe Saesen, Mieke Van Hemelrijck, Jan Bogaerts, Christopher M. Booth, Jan J. Cornelissen, Andre Dekker, Elizabeth A. Eisenhauer, Andre Freitas, Alessandro Gronchi, Miguel A. Hernan, Frank Hulstaert, Piet Ost, Petr Szturz, Helena M. Verkooijen, Michael Weller, Roger Wilson, Denis Lacombe, Winette T. van der Graaf
Summary: The precision medicine paradigm in oncology has sparked interest in integrating real-world data (RWD) into cancer research. RWD studies tend to focus on collecting and analyzing observational data, but randomized controlled trials (RCTs) have the potential to generate strong evidence. The European Organisation for Research and Treatment of Cancer (EORTC) prioritizes pragmatic trials and trials-within-cohorts to generate robust RWD, but will consider observational research based on the target trial principle if random allocation is not feasible. New EORTC-sponsored trials may also include concurrent prospective cohorts.
EUROPEAN JOURNAL OF CANCER
(2023)
Correction
Oncology
Fabio Conforti, Alessandro Gronchi, Nicholas Penel, Robin L. Jones, Javier M. Broto, Isabella Sala, Vincenzo Bagnardi, Andrea Napolitano, Laura Pala, Elisabetta Pennacchioli, Chiara Catania, Paola Queirolo, Giovanni Grigani, Alessandra Merlini, Silvia Stacchiotti, Alessandro Comandone, Bruno Vincenzi, Vittorio Quagliuolo, Alexia Bertuzzi, Antonella Boglione, Elena Palassini, Giacomo G. Baldi, Jean-Yves Blay, Thomas Ryckewaert, Maud Toulmonde, Antoine Italiano, Axel Le Cesne, Isabelle Ray-Coquard, Josefina Cruz, Carmen N. Hernandez-Leon, Javier M. Trufero, David da Silva Moura, Nadia H. Muniz, Tommaso De Pas
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Lucy-Rose Howroyd, Isabel Cornell, Charlotte Benson, Andrea Napolitano, Matthew Blackledge, Timothy Sumhonmun, Eleanor Moskovic, Christian Kelly-Morland, Margaret Adejolu, Robin L. Jones, Christina Messiou
Summary: The incidence of pseudoprogression in patients with metastatic or inoperable uterine leiomyosarcoma treated with first-line doxorubicin is 19%. However, Choi criteria were not consistently able to differentiate pseudoprogression from true progression. Symptomatically stable/improving patients may benefit from continued treatment despite initial radiological growth in tumor size.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Hans Gelderblom, Robin L. Jones, Jean-Yves Blay, Suzanne George, Margaret von Mehren, John R. Zalcberg, Yoon-Koo Kang, Albiruni Abdul Razak, Jonathan Trent, Steven Attia, Axel Le Cesne, Brittany L. Siontis, David Goldstein, Kjetil Boye, Cesar Sanchez, Neeltje Steeghs, Piotr Rutkowski, Mihaela Druta, Cesar Serrano, Neeta Somaiah, Ping Chi, Brooke Harrow, Claus Becker, William Reichmann, Matthew L. Sherman, Rodrigo Ruiz-Soto, Michael C. Heinrich, INTRIGUE Investigators
Summary: In the INTRIGUE trial, there was no significant difference in progression-free survival between ripretinib and sunitinib for advanced gastrointestinal stromal tumour (GIST) patients. The study compared the impact of these treatments on health-related quality of life (HRQoL) and found that patients receiving ripretinib had better HRQoL during the dosing period compared to patients receiving sunitinib.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Philip Heesen, Andreas Ranft, Vivek Bhadri, Benedicte Brichard, Stephane Collaud, Sona Cyprova, Hans Eich, Torben Ek, Hans Gelderblom, Jendrik Hardes, Lianne Haveman, Susanne Jabar, Wolfgang Hartmann, Dimosthenis Andreou, Peter Hauser, Josephine Kersting, Heribert Juergens, Jukka Kanerva, Thomas Kuehne, Anna Raciborska, Jelena Rascon, Arne Streitbuerger, Beate Timmermann, Yasmin Uhlenbruch, Uta Dirksen
Summary: This study analyzed the association between local therapy and event-free survival (EFS), overall survival (OS), and local recurrence (LR) in patients with Ewing sarcoma. The results showed that in certain situations, combination therapy with radiotherapy and surgery can improve the prognosis of patients. This provides important evidence for the personalized treatment of Ewing sarcoma.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
William D. Tap, Maitreyi G. Sharma, Marc Vallee, Bryan D. Smith, Matthew L. Sherman, Rodrigo Ruiz-Soto, Michiel van de Sande, R. Lor Randall, Nicholas M. Bernthal, Hans Gelderblom
Summary: TGCT is a rare neoplasm caused by upregulation of the CSF1 gene. Vimseltinib, an oral tyrosine kinase inhibitor, is being tested in the Phase III MOTION trial for its efficacy and safety in TGCT patients who are not suitable for surgery. Participants will receive vimseltinib or placebo in Part 1, followed by open-label vimseltinib treatment in Part 2.
Article
Radiology, Nuclear Medicine & Medical Imaging
Andrea G. Rockall, Xingfeng Li, Nicholas Johnson, Ioannis Lavdas, Shalini Santhakumaran, A. Toby Prevost, Shonit Punwani, Vicky Goh, Tara D. Barwick, Nishat Bharwani, Amandeep Sandhu, Harbir Sidhu, Andrew Plumb, James Burn, Aisling Fagan, Georg J. Wengert, Dow-Mu Koh, Krystyna Reczko, Qi Dou, Jane Warwick, Xinxue Liu, Christina Messiou, Nina Tunariu, Peter Boavida, Neil Soneji, Edward W. Johnston, Christian Kelly-Morland, Katja N. De Paepe, Heminder Sokhi, Kathryn Wallitt, Amish Lakhani, James Russell, Miriam Salib, Sarah Vinnicombe, Adam Haq, Eric O. Aboagye, Stuart Taylor, Ben Glocker
Summary: The study aimed to develop a machine learning algorithm to improve radiologists' sensitivity and specificity for metastasis detection in whole-body magnetic resonance imaging (WB-MRI). The results showed that using the algorithm can enhance the detection accuracy and reduce reading times for radiologists.
INVESTIGATIVE RADIOLOGY
(2023)
Article
Oncology
Amani Arthur, Matthew R. Orton, Robby Emsley, Sharon Vit, Christian Kelly-Morland, Dirk Strauss, Jason Lunn, Simon Doran, Hafida Lmalem, Axelle Nzokirantevye, Saskia Litiere, Sylvie Bonvalot, Rick Haas, Alessandro Gronchi, Dirk Van Gestel, Anne Ducassou, Chandrajit P. Raut, Pierre Meeus, Mateusz Spalek, Matthew Hatton, Cecile Le Pechoux, Khin Thway, Cyril Fisher, Robin Jones, Paul H. Huang, Christina Messiou
Summary: This study aimed to develop and independently validate a CT-based radiomics classification model for predicting histological type and grade in retroperitoneal leiomyosarcoma and liposarcoma.
Article
Oncology
Emanuela Palmerini, John H. Healey, Nicholas M. Bernthal, Sebastian Bauer, Hendrik Schreuder, Andreas Leithner, Javier Martin-Broto, Francois Gouin, Julio Lopez-Bastida, Hans Gelderblom, Eric L. Staals, Florence Mercier, Petra Laeis, Xin Ye, Michiel van de Sande
Summary: This study investigated the impact of diffuse-type Tenosynovial giant cell tumor (D-TGCT) on treatment strategies and quality of life for patients. The results showed that patients who switched to an active treatment strategy had higher scores for pain and interference, while patients who remained off-treatment had lower scores at the 2-year follow-up. These findings are important for guiding the treatment and management of D-TGCT.
Article
Radiology, Nuclear Medicine & Medical Imaging
Annemarie K. Knill, Matthew D. Blackledge, Andra Curcean, James Larkin, Samra Turajlic, Angela Riddell, Dow Mu Koh, Christina Messiou, Jessica M. Winfield
Summary: This study aims to establish the optimal diffusion weighting (b-value) for whole-body diffusion-weighted MRI (WB-DWI) to estimate the apparent diffusion coefficient (ADC) in patients with metastatic melanoma (MM). The results suggest that the optimal high b-value is 1100 s/mm(2) and higher b-values lead to increased geometric distortion and reduced signal.
EUROPEAN RADIOLOGY
(2023)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)
